Zhuhai Rundu Pharmaceutical Co.,Ltd. (002923.SZ) has issued an announcement regarding significant stock price fluctuations, stating that the company currently possesses a Class 1 innovative chemical drug, Norcoclaurine Hydrochloride Injection (Specification: 2ml:2.5mg), along with its active pharmaceutical ingredient, and the drug evaluation process is proceeding in an orderly manner. Innovative drug development is characterized by long cycles, substantial investment, and high risks; consequently, uncertainties remain regarding whether the drug will ultimately gain market approval, the timeline for any potential approval, and its subsequent production and sales performance post-launch, and it is not expected to significantly impact the company's financial performance in the short term.